Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings

ABSTRACT Introduction: Recent advances in the treatment and prevention of cryptococcal meningitis have the potential to decrease AIDS-related deaths. Areas covered: Targeted screening for asymptomatic cryptococcal antigenemia in persons with AIDS is a cost effective method for reducing early mortality in patients on antiretroviral therapy. For persons with symptomatic cryptococcal meningitis, optimal initial management with amphotericin and flucytosine improves survival compared to alternative therapies; however, amphotsericin is difficult to administer and flucytosine has not been available in middle or low income countries, where cryptococcal meningitis is most prevalent. Expert commentary: Improved care for cryptococcal meningitis patients in resource-limited settings is possible, and new treatment possibilities are emerging.

[1]  D. Lalloo,et al.  Changing epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa. , 2016, The Lancet. Infectious diseases.

[2]  J. Miranda,et al.  Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery , 2016, Neural regeneration research.

[3]  D. Boulware,et al.  Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Zachary J. Jarou,et al.  Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis , 2016 .

[5]  D. Boulware,et al.  Efficacy of Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis: an open-label dose-ranging study , 2016, The Lancet. Infectious diseases.

[6]  J. Adler-Moore,et al.  Comparison between liposomal formulations of amphotericin B. , 2016, Medical mycology.

[7]  E. Garvey,et al.  The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii , 2016, Antimicrobial Agents and Chemotherapy.

[8]  T. Harrison,et al.  Cryptococcal antigen screening in HIV-infected adults: let's get straight to the point. , 2015, AIDS.

[9]  D. Fitzgerald,et al.  Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia , 2015, AIDS.

[10]  D. Boulware,et al.  Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution , 2015, International journal of STD & AIDS.

[11]  D. Boulware,et al.  LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY , 2015, Revista do Instituto de Medicina Tropical de Sao Paulo.

[12]  D. Boulware,et al.  Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda , 2015, Antimicrobial Agents and Chemotherapy.

[13]  J. Perfect,et al.  AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial , 2015, Trials.

[14]  L. Guinness,et al.  Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial , 2015, The Lancet.

[15]  D. Krysan.  Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs. , 2015, Fungal genetics and biology : FG & B.

[16]  Benjamin J Park,et al.  Cryptococcal Antigen Screening and Early Antifungal Treatment to Prevent Cryptococcal Meningitis: A Review of the Literature , 2015, Journal of acquired immune deficiency syndromes.

[17]  M. Tanner,et al.  Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality , 2015, Open forum infectious diseases.

[18]  M. Noursadeghi,et al.  Cerebrospinal Fluid Cytokine Profiles Predict Risk of Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis , 2015, PLoS pathogens.

[19]  D. Boulware,et al.  Accuracy of Noninvasive Intraocular Pressure or Optic Nerve Sheath Diameter Measurements for Predicting Elevated Intracranial Pressure in Cryptococcal Meningitis , 2014, Open forum infectious diseases.

[20]  D. Boulware,et al.  Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings , 2014, Open forum infectious diseases.

[21]  D. Boulware,et al.  The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis , 2014, Clinical Infectious Diseases.

[22]  D. Boulware,et al.  Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. , 2014, The New England journal of medicine.

[23]  D. Fitzgerald,et al.  Cryptococcal Meningitis Management in Tanzania With Strict Schedule of Serial Lumber Punctures Using Intravenous Tubing Sets: An Operational Research Study , 2014, Journal of acquired immune deficiency syndromes.

[24]  J. Heitman,et al.  Estrogen Receptor Antagonists Are Anti-Cryptococcal Agents That Directly Bind EF Hand Proteins and Synergize with Fluconazole In Vivo , 2014, mBio.

[25]  D. Boulware,et al.  Unmasking Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome due to Granulocyte Colony-Stimulating Factor Use in a Patient with a Poorly Differentiated Germ Cell Neoplasm , 2014, Case Reports in Oncology.

[26]  D. Boulware,et al.  Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast , 2014, Emerging infectious diseases.

[27]  D. Boulware,et al.  Cryptococcus neoformans Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis , 2013, The Journal of infectious diseases.

[28]  Mark J Siedner,et al.  Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  N. Nakasujja,et al.  Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study , 2014, Metabolic Brain Disease.

[30]  M. Kamya,et al.  Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis. , 2013, Future virology.

[31]  Christina C. Chang,et al.  Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome , 2013, AIDS.

[32]  K. Kuntz,et al.  Cost-Effective Diagnostic Checklists for Meningitis in Resource-Limited Settings , 2013, Journal of acquired immune deficiency syndromes.

[33]  R. Heyderman,et al.  A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi , 2013, PloS one.

[34]  D. Boulware,et al.  Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update , 2013 .

[35]  R. Hamill.  Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity , 2013, Drugs.

[36]  D. Boulware,et al.  Diagnosis and Management of Cryptococcal Relapse. , 2013, Journal of AIDS & clinical research.

[37]  Robert D. Johnson,et al.  Analysis of sertraline in postmortem fluids and tissues in 11 aviation accident victims. , 2013, Journal of analytical toxicology.

[38]  S. Holland,et al.  Anti–GM-CSF Autoantibodies in Patients with Cryptococcal Meningitis , 2013, The Journal of Immunology.

[39]  D. Weissman,et al.  Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  J. Perfect,et al.  Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility Breakpoints , 2013, Antimicrobial Agents and Chemotherapy.

[41]  J. Farrar,et al.  Combination antifungal therapy for cryptococcal meningitis. , 2013, The New England journal of medicine.

[42]  J. Jarvis,et al.  Cryptococcal immune reconstitution inflammatory syndrome , 2013, Current opinion in infectious diseases.

[43]  M. Cogliati.  Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An Atlas of the Molecular Types , 2013, Scientifica.

[44]  D. Kontoyiannis,et al.  Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-γ. , 2012, Diagnostic microbiology and infectious disease.

[45]  O. Lortholary,et al.  Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS , 2012, AIDS.

[46]  S. Lawn,et al.  Cryptococcal Antigen Screening and Preemptive Therapy in Patients Initiating Antiretroviral Therapy in Resource-Limited Settings , 2012, Journal of the International Association of Physicians in AIDS Care.

[47]  D. Boulware,et al.  Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis , 2012, PLoS medicine.

[48]  S. Jaffar,et al.  A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis , 2012, AIDS.

[49]  L. Bekker,et al.  Adjunctive interferon-&ggr; immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial , 2012, AIDS.

[50]  M. Sachs,et al.  The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections , 2012, Antimicrobial Agents and Chemotherapy.

[51]  D. Boulware,et al.  Integrating Cryptococcal Antigen Screening and Pre-Emptive Treatment into Routine HIV Care , 2012, Journal of acquired immune deficiency syndromes.

[52]  S. Jaffar,et al.  Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  S. Jaffar,et al.  Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. , 2012, The Journal of infection.

[54]  J. Baddley,et al.  Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya , 2011, Mycoses.

[55]  J. Miller,et al.  Long-term follow-up and survival of antiretroviral-naïve patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa , 2011, International journal of STD & AIDS.

[56]  S. Lockhart,et al.  Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates Obtained through Population-Based Surveillance in South Africa in 2002-2003 and 2007-2008 , 2011, Antimicrobial Agents and Chemotherapy.

[57]  Tracy L. Bergemann,et al.  Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study , 2010, PLoS medicine.

[58]  L. Haddow,et al.  Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. , 2010, The Lancet. Infectious diseases.

[59]  David R Boulware,et al.  Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. , 2010, The Journal of infectious diseases.

[60]  W. El-Sadr,et al.  Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  J. Farrar,et al.  A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease , 2010, BMC infectious diseases.

[62]  J. Jarvis,et al.  Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. , 2010, The Journal of infection.

[63]  Philimon N. Gona,et al.  Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  J. Jarvis,et al.  Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. , 2010, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[65]  J. Perfect,et al.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  J. Jarvis,et al.  Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure , 2010, AIDS.

[67]  Amy M. Sitapati,et al.  Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  S. Jaffar,et al.  Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  J. Sobel,et al.  A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  J. Jarvis,et al.  High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. , 2009, AIDS.

[71]  A. Zolopa,et al.  Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial , 2009, PloS one.

[72]  S. Jaffar,et al.  Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures , 2009, AIDS.

[73]  K. Wannemuehler,et al.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS , 2009, AIDS.

[74]  S. Jaffar,et al.  Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  D. Boulware,et al.  Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  L. Bekker,et al.  Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[77]  M. Alvarez,et al.  Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy , 2006, AIDS.

[78]  P. Newton,et al.  A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  E. Brummer,et al.  Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans. , 2002, Medical mycology.

[80]  M. Saag,et al.  Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis , 2000 .

[81]  M. Saag,et al.  A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  D. Debruyne.  Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic Mycoses , 1997, Clinical pharmacokinetics.

[83]  M. Saag,et al.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[84]  D. Richman,et al.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. , 1991, The New England journal of medicine.